
    
      Patients with type 1 or 2 Diabetes mellitus will be recruited according to eligibility
      criteria. Bone marrow mononuclear cells (BMMCs) will be separated from the bone marrow
      aspirate of each patient and be directly delivered to pancreas via splenic artery with the
      distal lumen occlusion through an arterial catheter. All patients will be explained in
      details about the procedures involved in BMMC transplantation and sign the informed consent
      for the study; The Ethics Committee of Qilu hospital, ShanDong university approved the
      treatment protocol. All patients undergo scheduled follow-up evaluations for 5 years after
      transplantation. Clinical, hematological, metabolical evaluations are performed to analyses
      the effect of the transplant, Patients fitting the inclusion criteria but not agreeing to
      perform the transplantation are the control group and will received the regular OHA and/or
      insulin therapy .They are followed in parallel with transplanted patients and will be
      subjected to the same follow-up management including extensive endocrinological monitoring,
      diet and exercise program as transplantation patients during the follow-up.
    
  